POLYMYOSITIS

This study tested the long-term safety and effectiveness of a drug called KZR-616 in 18 adults with active polymyositis or dermatomyositis, rare diseases that cause muscle inflammation and weakness. Participants who completed an earlier study received weekly injections of KZR-616…

This Phase 2 trial tested a drug called KZR-616 (zetomipzomib) in 25 adults with active polymyositis or dermatomyositis, two rare diseases that cause muscle inflammation and weakness. Participants received either the drug or a placebo for 16 weeks, then switched to the other trea…

This study looked at whether whole body MRI can accurately diagnose inflammatory myopathies—a group of muscle diseases causing weakness and damage. Researchers compared MRI results with muscle biopsies in 139 people suspected of having these conditions. If MRI proves reliable, it…

This study tested whether a personalized exercise program can improve daily function and quality of life for people with dermatomyositis or polymyositis, two rare diseases that cause muscle weakness and inflammation. 80 adults with stable muscle impairment took part. The program …

This study looked at 719 people, including patients with autoimmune connective tissue diseases like myositis, their blood relatives, and healthy volunteers. Researchers collected blood samples and medical histories to find genetic and environmental factors that may trigger these …

This study looked at a new way to measure muscle function in people with inflammatory myopathies (diseases that cause muscle weakness). Researchers compared a simple test called the Myositis Functional Index-3 with advanced computerised muscle testing. They also tested whether a …